NCT06193408View on ClinicalTrials.gov

Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 11, 2024

Primary Completion Date

August 11, 2024

Study Completion Date

September 8, 2024

Conditions
Cholera
Interventions
DRUG

VR-AD-1005

oral capsule

DRUG

Placebo

oral capsule

Trial Locations (1)

Unknown

Icddr,b, Dhaka

Sponsors
All Listed Sponsors
lead

Hunazine Biotech S.L.

INDUSTRY

NCT06193408 - Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera | Biotech Hunter | Biotech Hunter